ATE235462T1 - Metalloproteinase-inhibitoren - Google Patents

Metalloproteinase-inhibitoren

Info

Publication number
ATE235462T1
ATE235462T1 AT98933813T AT98933813T ATE235462T1 AT E235462 T1 ATE235462 T1 AT E235462T1 AT 98933813 T AT98933813 T AT 98933813T AT 98933813 T AT98933813 T AT 98933813T AT E235462 T1 ATE235462 T1 AT E235462T1
Authority
AT
Austria
Prior art keywords
metalloproteinase inhibitors
metalloproteinase
inhibitors
useful
compound
Prior art date
Application number
AT98933813T
Other languages
English (en)
Inventor
Raymond Paul Beckett
Road Watlington
Fionna Mitchell Martin
Andrew Miller
Richard Simon Todd
Mark Whittaker
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Application granted granted Critical
Publication of ATE235462T1 publication Critical patent/ATE235462T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
AT98933813T 1997-07-18 1998-07-16 Metalloproteinase-inhibitoren ATE235462T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715030A GB9715030D0 (en) 1997-07-18 1997-07-18 Metalloproteinase inhibitors
PCT/GB1998/002092 WO1999003826A2 (en) 1997-07-18 1998-07-16 Metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
ATE235462T1 true ATE235462T1 (de) 2003-04-15

Family

ID=10815986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98933813T ATE235462T1 (de) 1997-07-18 1998-07-16 Metalloproteinase-inhibitoren

Country Status (8)

Country Link
US (2) US6271262B1 (de)
EP (1) EP0998454B1 (de)
JP (1) JP2001510182A (de)
AT (1) ATE235462T1 (de)
AU (1) AU8350698A (de)
DE (1) DE69812634D1 (de)
GB (1) GB9715030D0 (de)
WO (1) WO1999003826A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816341A1 (de) 1996-07-04 1998-01-07 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von chiralen Bernsteinsäurederivaten
NZ509241A (en) 1998-08-07 2003-08-29 Du Pont Pharm Co Succinoylamino lactams as inhibitors of alpha-beta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
IL142816A0 (en) 1998-12-24 2002-03-10 Du Pont Pharm Co SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
EP1218377A1 (de) 1999-10-08 2002-07-03 Bristol-Myers Squibb Pharma Company Amino-lactam-sulfonamide als inhibitoren der bildung von a-beta-amyloid-protein
EP1261610A2 (de) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino-carbocyclen und -heterocyclen als hemmer der a-beta-proteinbildung
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
US6713476B2 (en) 2000-04-03 2004-03-30 Dupont Pharmaceuticals Company Substituted cycloalkyls as inhibitors of a beta protein production
WO2001074783A1 (en) * 2000-04-03 2001-10-11 Dupont Pharmaceuticals Company Cyclic lactams as inhibitors of a βετα protein production
US6632812B2 (en) 2000-04-11 2003-10-14 Dupont Pharmaceuticals Company Substituted lactams as inhibitors of Aβ protein production
AU783857B2 (en) 2000-06-01 2005-12-15 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a beta protein production
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
CA2851462A1 (en) * 2003-01-08 2004-07-29 University Of Washington Antibacterial agents
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
CA2934114A1 (en) * 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
EP2847168A1 (de) 2012-05-10 2015-03-18 Achaogen, Inc. Antibakterielle wirkstoffe
CN114401992A (zh) 2019-07-05 2022-04-26 艾欧麦克斯治疗股份公司 结合igsf11（vsig3）的igc2的抗体及其用途
US20240010720A1 (en) 2020-07-06 2024-01-11 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2058797A1 (en) * 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US6013792A (en) 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
AUPO048296A0 (en) 1996-06-14 1996-07-11 Fujisawa Pharmaceutical Co., Ltd. New compound and its preparation

Also Published As

Publication number Publication date
EP0998454B1 (de) 2003-03-26
JP2001510182A (ja) 2001-07-31
AU8350698A (en) 1999-02-10
GB9715030D0 (en) 1997-09-24
US6271262B1 (en) 2001-08-07
WO1999003826A3 (en) 1999-04-01
US6358987B1 (en) 2002-03-19
DE69812634D1 (de) 2003-04-30
EP0998454A2 (de) 2000-05-10
WO1999003826A2 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
DE69812634D1 (de) Metalloproteinase-inhibitoren
ATE227264T1 (de) Metalloproteinase-inhibitoren
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
GB9919776D0 (en) Compoujnds
SE0000540D0 (sv) New compounds
ES2088839T1 (es) Compuestos inhibidores de la proteasa retroviral.
CY1107634T1 (el) Φαρμακευτικη συνθεση
EA199900366A1 (ru) Гетероарильные производные сукцинамидов и их применение в качестве ингибиторов металлопротеиназы
ATE165817T1 (de) Metalloproteinaseinhibitoren
PT1193270E (pt) Pirrolobenzodiazepinas
DK1001930T3 (da) N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser
ES2135347B1 (es) Hidroxifeniltriazinas.
IT1283588B1 (it) Miscela sinergica di agenti stabilizzanti
DE60335359D1 (de) Phthalazinonderivate
ATE228111T1 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
SE0100903D0 (sv) Compounds
EA200000094A1 (ru) Способ получения замещенного пергидроизоиндола
SE0103710D0 (sv) Compounds
MY128164A (en) Compounds
EA199800200A1 (ru) Ингибиторы пролилэндопептидазы
SV1998000088A (es) Compuestos farmaceuticos
TR200001353T2 (tr) Metaloproteinaz inhibitörleri
DE69717147T2 (de) Thrombin inhibitoren
UY24326A1 (es) Nuevas piperidinas.
MY117874A (en) Metalloproteinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties